Peptide Comparison
AdipotidevsTirzepatide
A targeted fat-destroying peptide that works like a smart missile, cutting off blood supply to fat cells and causing rapid weight loss in primate studies.
The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.
At a Glance
Quick
comparison
Dose Range
Adipotide
0.1–0.43 mg/kg
Tirzepatide
2.5–15 mg
Frequency
Adipotide
Once daily
Tirzepatide
Once weekly
Administration
Adipotide
Subcutaneous injection
Tirzepatide
Subcutaneous injection
Cycle Length
Adipotide
4-6 weeks
Tirzepatide
Ongoing/indefinite
Onset Speed
Adipotide
Moderate (1-2 weeks)
Tirzepatide
Moderate (1-2 weeks)
Evidence Level
Adipotide
Strong preclinical (extensive animal studies)
Tirzepatide
Strong human trials (Phase 3 or FDA approved)
Efficacy
Benefit
ratings
Fat Elimination
Metabolic Improvement
Speed of Results
Weight Loss
Appetite Control
Blood Sugar Control
Technical Data
Compound
specifications
Adipotide
Molecular Formula
C111H206N36O28S2
Molecular Weight
2611.41 g/mol
Half-Life
~24 hours
Bioavailability
High (subcutaneous injection)
CAS Number
859216-15-2
Tirzepatide
Molecular Formula
C225H348N48O68
Molecular Weight
4813.45 g/mol
Half-Life
Approximately 5 days (120 hours)
Bioavailability
~80% (subcutaneous)
CAS Number
2023788-19-2
Protocols
Dosing
tiers
Adipotide
Tirzepatide
Applications
Best
suited for
Adipotide
Targeted White Fat Reduction
Adipotide specifically seeks out and destroys the blood vessels feeding white adipose tissue. Unlike diet or exercise that shrink fat cells, this peptide actually eliminates fat tissue by cutting off its blood supply - a completely unique mechanism.
Stubborn Fat Deposits
Because it targets the vasculature of fat tissue directly, Adipotide may be particularly effective for stubborn fat deposits that resist traditional methods. The peptide homes in on prohibitin receptors found specifically on blood vessels supplying fat tissue.
Improving Insulin Resistance
Primate studies showed remarkable improvements in insulin sensitivity - treated monkeys used about 50% less insulin after treatment. This makes it interesting for research into obesity-related metabolic dysfunction.
Research Applications
As a pioneering vascular-targeting peptide, Adipotide represents a new class of potential therapeutics. Its unique mechanism of targeting specific tissue vasculature has implications beyond obesity research.
Tirzepatide
People Who Want Maximum Weight Loss Results
If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close.
Those Who Haven't Succeeded with Semaglutide
Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss.
People with Type 2 Diabetes Needing Aggressive Control
Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health.
Individuals Looking to Transform Their Relationship with Food
Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you.
Safety Profile
Side
effects
Adipotide
Common
- Elevated Serum Creatinine
- Proteinuria
- Glucosuria
- Reduced Appetite
Uncommon
- Mild Dehydration
- Injection Site Reactions
Serious
- Renal Tubular Dysfunction
Tirzepatide
Common
- Nausea
- Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Thinning (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Research Status
Safety
& evidence
Adipotide
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
Adipotide has been extensively studied in mice, rats, and three species of primates with consistent results. The primary safety concern is dose-dependent kidney effects, which were reversible upon stopping treatment in all studies. No cardiovascular, neurological, or hepatic adverse events were observed. The compound shows remarkable selectivity - lean animals given the same doses experienced no weight loss, suggesting it specifically targets excess fat tissue.
Contraindications
- xKidney disease or impaired renal function
- xPregnancy or breastfeeding
- xActive infections or compromised immune system
- xHistory of severe allergic reactions to peptides
- xDehydration or conditions affecting fluid balance
Tirzepatide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. The FDA approved it after thorough safety review. While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma (MTC)
- xMultiple Endocrine Neoplasia syndrome type 2 (MEN2)
- xHistory of serious allergic reaction to tirzepatide or any GLP-1/GIP medication
- xCurrent or recent pancreatitis
- xPregnancy or planning to become pregnant
Decision Guide
Which is
right for you?
Choose Adipotide if...
- Targeted fat reduction
- Improving insulin resistance
- Reducing stubborn white adipose tissue
- Research into vascular-targeted therapies
Choose Tirzepatide if...
- Maximum weight loss results
- Long-term obesity management
- Type 2 diabetes control
- Metabolic health improvement